Enzymotec to price initial public stock sale between $16.00 and $18.00

BofA Merrill Lynch, Jefferies are joint bookrunning managers for deal

By Devika Patel

Knoxville, Tenn., Sept. 16 - Enzymotec Ltd. will sell 4,412,000 ordinary shares in its initial public offering with a greenshoe option of 661,800 additional shares, according to a Form F-1/A filed Monday with the Securities and Exchange Commission. The deal was announced Aug. 22.

The shares will be sold at a price expected to be between $16.00 and $18.00 per share.

BofA Merrill Lynch and Jefferies are the joint bookrunning managers. Wells Fargo Securities, Canaccord Genuity and Wedbush Securities are the co-managers.

Proceeds will be used for working capital requirements and other general corporate purposes.

The nutritional ingredients and medical foods company is based in Migdal Ha'Emeq, Israel. The company intends to list its common stock on the Nasdaq stock exchange under the symbol "ENZY."

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.